{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:40:42Z","timestamp":1790422842679,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The rising incidence of breast cancer (BC) among Egyptian females with a mortality rate of 11% and younger age at diagnosis implied the study of the interplay of <jats:italic>BRCA<\/jats:italic> gene variants with other BC risk factors. The study enrolled 500 BC Egyptian females with a mean age of 47.29\u2009\u00b1\u200913.26 years for whom <jats:italic>BRCA<\/jats:italic>1\/2 testing was offered. A history of BC and\/or other related cancer was recorded for all patients. Peripheral blood samples were obtained for genomic DNA extraction in view of germline <jats:italic>BRCA<\/jats:italic> gene testing on the MiSeq platform. A positive family history was reported in 352 patients (70.4%). Patients with hormone receptor\u2013positive (HR+) BC constituted 195 cases (39%) cases, while 305 patients (61%) had hormone receptor\u2013negative (HR\u2212) BC. Among the HR\u2212\u2009group, 268 patients (53%) had triple-negative BC (TNBC), and 37 patients had low estrogen receptor (ER) (1\u201310%) and\/ or low progesterone receptor (PR) expression with HER2 negative status. Patients with HER2-positive BC were excluded from the enrollment and directed to specific targeted therapy. Variants were classified according to the American College of Medical Genetics (ACMG) and the Association for Molecular Pathology (AMP) criteria. Carriers of g<jats:italic>BRCA<\/jats:italic>1\/2 PVs\/LPVs were 58 patients (11.6%) of whom 34 (6.8%) had <jats:italic>BRCA<\/jats:italic>1 PVs\/LPVs and 24 (4.8%) had <jats:italic>BRCA<\/jats:italic>2 PVs\/LPVs. Patients with TNBC demonstrated a higher rate of g<jats:italic>BRCA<\/jats:italic>1\/2 PVs\/LPVs (17.5%). We recorded 55 PVs\/LPVs in both genes, 44 single nucleotide variants (SNVs), and 11 copy number variations (CNVs). Three novel g<jats:italic>BRCA<\/jats:italic>1 LPVs; c.2791del, c.361G&gt;T and c.4431dup and two novel g<jats:italic>BRCA<\/jats:italic>2 LPVs; g<jats:italic>BRCA<\/jats:italic>2 c.3139del and c.5690 dup were identified. Variants of uncertain significance (VUS) were found in 22 patients, of whom 13 (59%) had a positive family history of breast\/ovarian cancer. Genomic testing for <jats:italic>BRCA<\/jats:italic>1\/2 status as part of a routine BC diagnostic workup contributes to comprehensive BC risk assessment.<\/jats:p>\n          <jats:p>\n            <jats:italic>Trial registration:<\/jats:italic> Egyptian National Cancer Institute IRB approval number: 2301-305-051. Date of registration: 24th Jan 2023.<\/jats:p>","DOI":"10.1038\/s41598-025-09810-5","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T08:34:49Z","timestamp":1752827689000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Mutational spectrum of BRCA genes in Egyptian patients with breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Wafaa","family":"Elmetnawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer","family":"ElNahas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Bassiony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"ElNahass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"4","key":"9810_CR1","doi-asserted-by":"publisher","first-page":"221","DOI":"10.21608\/mjmr.2022.218094","volume":"31","author":"EM Mahfouz","year":"2020","unstructured":"Mahfouz, E. M. Clinical characteristics of breast cancer in young women \u2264 40 years old-Minia-Egypt. Minia J. Med. Res. 31(4), 221\u2013227 (2020).","journal-title":"Minia J. Med. Res."},{"key":"9810_CR2","unstructured":"Alorabi, M., Elghazawy, H. et al. Cancer control in Egypt: Investing in health. (The ASCO Post, 2021)."},{"key":"9810_CR3","doi-asserted-by":"publisher","first-page":"e2200387","DOI":"10.1200\/GO.22.00387","volume":"9","author":"HA Azim","year":"2023","unstructured":"Azim, H. A. et al. Clinicopathologic features of breast cancer in Egypt\u2014contemporary profile and future needs: A systematic review and meta-analysis. JCO Glob. Oncol. 9, e2200387 (2023).","journal-title":"JCO Glob. Oncol."},{"key":"9810_CR4","doi-asserted-by":"publisher","DOI":"10.47750\/pnr.2023.14.02.24","author":"HF Ahmed","year":"2023","unstructured":"Ahmed, H. F. et al. Cost effectiveness analysis of breast cancer screening in upper-and low-middle income countries focusing on Egypt: A systematic review. J. Pharm. Negative Results https:\/\/doi.org\/10.47750\/pnr.2023.14.02.24 (2023).","journal-title":"J. Pharm. Negative Results"},{"issue":"2","key":"9810_CR5","doi-asserted-by":"publisher","first-page":"515","DOI":"10.4103\/ejs.ejs_316_23","volume":"43","author":"MA Mohammed","year":"2024","unstructured":"Mohammed, M. A. et al. Retrospective descriptive analysis of the demographic and clinicopathological presentation of breast cancer patients in Kasr Al-Ainy Hospital over 5 years. Egypt. J. Surg. 43(2), 515\u2013523 (2024).","journal-title":"Egypt. J. Surg."},{"issue":"2","key":"9810_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21608\/efmj.2017.67591","volume":"1","author":"TM Farahat","year":"2017","unstructured":"Farahat, T. M. et al. Effect of family history on clinical and pathological characteristics of breast cancer: A hospital-based study in Egypt. Egypt. Family Med. J. 1(2), 1\u201314 (2017).","journal-title":"Egypt. Family Med. J."},{"key":"9810_CR7","unstructured":"American Cancer Society. (n.d.). Breast cancer risk factors you cannot change. Retrieved from https:\/\/www.cancer.org\/cancer\/breast-cancer\/risk-and-prevention\/breast-cancer-risk-factors-you-cannot-change.html"},{"key":"9810_CR8","unstructured":"Petrucelli, N., Daly, M. B. et al. BRCA1-and BRCA2-associated hereditary breast and ovarian cancer (2022)."},{"key":"9810_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3389\/fonc.2020.00301","volume":"10","author":"S Wu","year":"2020","unstructured":"Wu, S. et al. Molecular mechanisms of PALB2 function and its role in breast cancer management. Front. Oncol. 10, 301 (2020).","journal-title":"Front. Oncol."},{"issue":"12","key":"9810_CR10","doi-asserted-by":"publisher","first-page":"e1007752","DOI":"10.1371\/journal.pgen.1007752","volume":"14","author":"MS Cline","year":"2018","unstructured":"Cline, M. S. et al. BRCA Challenge: BRCA exchange as a global resource for variants in BRCA1 and BRCA2. PLoS Genet. 14(12), e1007752 (2018).","journal-title":"PLoS Genet."},{"issue":"5","key":"9810_CR11","doi-asserted-by":"publisher","first-page":"e202101263","DOI":"10.26508\/lsa.202101263","volume":"5","author":"J Li","year":"2022","unstructured":"Li, J. et al. Human BRCA pathogenic variants were originated during recent human history. Life Sci. Alliance 5(5), e202101263 (2022).","journal-title":"Life Sci. Alliance"},{"issue":"5","key":"9810_CR12","doi-asserted-by":"publisher","first-page":"5741","DOI":"10.1002\/jcp.27464","volume":"234","author":"M Mahdavi","year":"2019","unstructured":"Mahdavi, M. et al. Hereditary breast cancer; Genetic penetrance and current status with BRCA. J. Cell. Physiol. 234(5), 5741\u20135750 (2019).","journal-title":"J. Cell. Physiol."},{"key":"9810_CR13","doi-asserted-by":"publisher","first-page":"102668","DOI":"10.1016\/j.dnarep.2019.102668","volume":"81","author":"AR Venkitaraman","year":"2019","unstructured":"Venkitaraman, A. R. How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility?. DNA Repair 81, 102668 (2019).","journal-title":"DNA Repair"},{"issue":"1","key":"9810_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41523-021-00317-6","volume":"7","author":"JS Herzog","year":"2021","unstructured":"Herzog, J. S. et al. Genetic epidemiology of BRCA1-and BRCA2-associated cancer across Latin America. NPJ Breast Cancer 7(1), 107 (2021).","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"9810_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12885-022-09181-4","volume":"22","author":"O ElBiad","year":"2022","unstructured":"ElBiad, O. et al. Prevalence of specific and recurrent\/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa. BMC Cancer 22(1), 208 (2022).","journal-title":"BMC Cancer"},{"key":"9810_CR16","first-page":"1","volume":"4","author":"O Abulkhair","year":"2018","unstructured":"Abulkhair, O. et al. Prevalence of BRCA1 and BRCA2 mutations among high-risk Saudi patients with breast cancer. J. Global Oncol. 4, 1\u20139 (2018).","journal-title":"J. Global Oncol."},{"key":"9810_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07352-9","volume":"20","author":"J Bakkach","year":"2020","unstructured":"Bakkach, J. et al. Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: A series from north of Morocco. BMC Cancer 20, 1\u20138 (2020).","journal-title":"BMC Cancer"},{"key":"9810_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12920-017-0244-7","volume":"10","author":"N Jalkh","year":"2017","unstructured":"Jalkh, N. et al. Next-generation sequencing in familial breast cancer patients from Lebanon. BMC Med. Genom. 10, 1\u201312 (2017).","journal-title":"BMC Med. Genom."},{"issue":"1","key":"9810_CR19","first-page":"8362179","volume":"2020","author":"H Abdel-Razeq","year":"2020","unstructured":"Abdel-Razeq, H. et al. Patterns and prevalence of germline BRCA1 and BRCA2 mutations among high-risk breast cancer patients in Jordan: A study of 500 patients. J. Oncol. 2020(1), 8362179 (2020).","journal-title":"J. Oncol."},{"issue":"11","key":"9810_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1002\/humu.23842","volume":"40","author":"Y Laitman","year":"2019","unstructured":"Laitman, Y. et al. The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Hum. Mutat. 40(11), e1\u2013e23 (2019).","journal-title":"Hum. Mutat."},{"key":"9810_CR21","doi-asserted-by":"publisher","first-page":"1132816","DOI":"10.3389\/fonc.2023.1132816","volume":"13","author":"S Azadnajafabad","year":"2023","unstructured":"Azadnajafabad, S. et al. Burden of breast cancer and attributable risk factors in the North Africa and Middle East region, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Front. Oncol. 13, 1132816 (2023).","journal-title":"Front. Oncol."},{"issue":"1","key":"9810_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40246-022-00447-3","volume":"17","author":"J Kim","year":"2023","unstructured":"Kim, J. et al. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1\/2 mutations. Hum. Genom. 17(1), 2 (2023).","journal-title":"Hum. Genom."},{"issue":"33","key":"9810_CR23","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1200\/JCO.2010.33.6446","volume":"29","author":"E Lee","year":"2011","unstructured":"Lee, E. et al. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: Results from a population-based study of young women. J. Clin. Oncol. 29(33), 4373\u20134380 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"9810_CR24","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1038\/s41467-020-17537-2","volume":"11","author":"D Glodzik","year":"2020","unstructured":"Glodzik, D. et al. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers. Nat. Commun. 11(1), 3747 (2020).","journal-title":"Nat. Commun."},{"issue":"1","key":"9810_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41523-023-00600-8","volume":"9","author":"L Vidarsdottir","year":"2023","unstructured":"Vidarsdottir, L. et al. Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients. NPJ Breast Cancer 9(1), 95 (2023).","journal-title":"NPJ Breast Cancer"},{"key":"9810_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/oso\/9780195168655.003.0014","volume-title":"The Oxford textbook of clinical research ethics","author":"RE Ashcroft","year":"2008","unstructured":"Ashcroft, R. E. The declaration of Helsinki. In The Oxford textbook of clinical research ethics 141\u2013148 (Oxford University Press, New York, 2008)."},{"issue":"17","key":"9810_CR27","doi-asserted-by":"publisher","first-page":"E601","DOI":"10.1503\/cmaj.212097","volume":"194","author":"DR Brenner","year":"2022","unstructured":"Brenner, D. R. et al. Projected estimates of cancer in Canada in 2022. CMAJ 194(17), E601\u2013E607 (2022).","journal-title":"CMAJ"},{"issue":"7","key":"9810_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.3390\/cancers15071923","volume":"15","author":"RB Basmadjian","year":"2023","unstructured":"Basmadjian, R. B. et al. The association between early-onset diagnosis and clinical outcomes in triple-negative breast cancer: A systematic review and meta-analysis. Cancers 15(7), 1923 (2023).","journal-title":"Cancers"},{"issue":"6","key":"9810_CR29","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge, S. B. & Compton, C. C. The American Joint Committee on Cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann. Surg. Oncol. 17(6), 1471\u20131474 (2010).","journal-title":"Ann. Surg. Oncol."},{"issue":"5","key":"9810_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41431-023-01507-5","volume":"32","author":"T McDevitt","year":"2024","unstructured":"McDevitt, T. et al. EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer. Eur. J. Hum. Genet. 32(5), 479\u2013488 (2024).","journal-title":"Eur. J. Hum. Genet."},{"issue":"9","key":"9810_CR31","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1016\/j.ajhg.2024.07.013","volume":"111","author":"MT Parsons","year":"2024","unstructured":"Parsons, M. T. et al. Evidence-based recommendations for gene-specific ACMG\/AMP variant classification from the ClinGen ENIGMA BRCA1 and BRCA2 variant curation expert panel. Am. J. Human Genet. 111(9), 2044\u20132058 (2024).","journal-title":"Am. J. Human Genet."},{"issue":"5","key":"9810_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/humu.21441","volume":"32","author":"P M\u00f8ller","year":"2011","unstructured":"M\u00f8ller, P. et al. A simplified method for segregation analysis (SISA) to determine penetrance and expression of a genetic variant in a family. Hum. Mutat. 32(5), 568\u2013571 (2011).","journal-title":"Hum. Mutat."},{"issue":"7571","key":"9810_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/nature15393","volume":"526","author":"GP Consortium","year":"2015","unstructured":"Consortium, G. P. A global reference for human genetic variation. Nature 526(7571), 68 (2015).","journal-title":"Nature"},{"key":"9810_CR34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. The ensembl variant effect predictor. Genom. Biol. 17, 122 (2016).","journal-title":"Genom. Biol."},{"issue":"8","key":"9810_CR35","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1136\/jmedgenet-2020-107003","volume":"58","author":"AC Gunning","year":"2021","unstructured":"Gunning, A. C. et al. Assessing performance of pathogenicity predictors using clinically relevant variant datasets. J. Med. Genet. 58(8), 547\u2013555 (2021).","journal-title":"J. Med. Genet."},{"issue":"1","key":"9810_CR36","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12920-022-01270-4","volume":"15","author":"A Kwong","year":"2022","unstructured":"Kwong, A. et al. How does re-classification of variants of unknown significance (VUS) impact the management of patients at risk for hereditary breast cancer?. BMC Med. Genom. 15(1), 122 (2022).","journal-title":"BMC Med. Genom."},{"issue":"D1","key":"9810_CR37","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: Improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46(D1), D1062\u2013D1067 (2018).","journal-title":"Nucleic Acids Res."},{"key":"9810_CR38","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10549-009-0613-9","volume":"122","author":"J Del Valle","year":"2010","unstructured":"Del Valle, J. et al. Identification and comprehensive characterization of large genomic rearrangements in the BRCA1 and BRCA2 genes. Breast Cancer Res. Treatment 122, 733\u2013743 (2010).","journal-title":"Breast Cancer Res. Treatment"},{"issue":"3","key":"9810_CR39","doi-asserted-by":"publisher","first-page":"e93306","DOI":"10.1371\/journal.pone.0093306","volume":"9","author":"L Fachal","year":"2014","unstructured":"Fachal, L. et al. Large genomic rearrangements of BRCA1 and BRCA2 among patients referred for genetic analysis in Galicia (NW Spain): Delimitation and mechanism of three novel BRCA1 rearrangements. PLoS ONE 9(3), e93306 (2014).","journal-title":"PLoS ONE"},{"key":"9810_CR40","doi-asserted-by":"publisher","first-page":"898916","DOI":"10.3389\/fonc.2022.898916","volume":"12","author":"D Hua","year":"2022","unstructured":"Hua, D. et al. Next-generation sequencing based detection of BRCA1 and BRCA2 large genomic rearrangements in Chinese cancer patients. Front. Oncol. 12, 898916 (2022).","journal-title":"Front. Oncol."},{"issue":"11","key":"9810_CR41","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.3390\/ijms25116274","volume":"25","author":"V Ea","year":"2024","unstructured":"Ea, V. et al. BRCA1 intragenic duplication combined with a likely pathogenic TP53 variant in a patient with triple-negative breast cancer: Clinical risk and management. Int. J. Mol. Sci. 25(11), 6274 (2024).","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"9810_CR42","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/humu.23113","volume":"37","author":"C B\u00e9roud","year":"2016","unstructured":"B\u00e9roud, C. et al. BRCA share: A collection of clinical BRCA gene variants. Hum. Mutat. 37(12), 1318\u20131328 (2016).","journal-title":"Hum. Mutat."},{"issue":"6","key":"9810_CR43","doi-asserted-by":"publisher","first-page":"e677","DOI":"10.1002\/mgg3.677","volume":"7","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Prevalence of BRCA1 and BRCA2 gene mutations in Chinese patients with high-risk breast cancer. Mol. Genet. Genomic Med. 7(6), e677 (2019).","journal-title":"Mol. Genet. Genomic Med."},{"issue":"1","key":"9810_CR44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12920-023-01772-9","volume":"17","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients. BMC Med. Genomics 17(1), 3 (2024).","journal-title":"BMC Med. Genomics"},{"key":"9810_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong, N. et al. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin. Epidemiol. 11, 543\u2013561 (2019).","journal-title":"Clin. Epidemiol."},{"issue":"9","key":"9810_CR46","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1158\/1541-7786.MCR-19-1108","volume":"18","author":"S Park","year":"2020","unstructured":"Park, S. et al. Clinical characteristics and exploratory genomic analyses of germline BRCA1 or BRCA2 mutations in breast cancer. Mol. Cancer Res. 18(9), 1315\u20131325 (2020).","journal-title":"Mol. Cancer Res."},{"key":"9810_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L. et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 1\u201313 (2020).","journal-title":"Breast Cancer Res."},{"issue":"13","key":"9810_CR48","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1001\/jama.2014.5985","volume":"313","author":"TR Rebbeck","year":"2015","unstructured":"Rebbeck, T. R. et al. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313(13), 1347\u20131361 (2015).","journal-title":"JAMA"},{"issue":"5","key":"9810_CR49","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.3892\/ijo.2012.1595","volume":"41","author":"S Novakovi\u0107","year":"2012","unstructured":"Novakovi\u0107, S. et al. Novel BRCA1 and BRCA2 pathogenic mutations in Slovene hereditary breast and ovarian cancer families. Int. J. Oncol. 41(5), 1619\u20131627 (2012).","journal-title":"Int. J. Oncol."},{"key":"9810_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13053-017-0079-4","volume":"15","author":"W Jian","year":"2017","unstructured":"Jian, W. et al. Clinical and genetic characterization of hereditary breast cancer in a Chinese population. Hered. Cancer Clin. Pract. 15, 1\u20139 (2017).","journal-title":"Hered. Cancer Clin. Pract."},{"key":"9810_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13053-019-0105-9","volume":"17","author":"C Farra","year":"2019","unstructured":"Farra, C. et al. BRCA mutation screening and patterns among high-risk Lebanese subjects. Hered. Cancer Clin. Pract. 17, 1\u20137 (2019).","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"5","key":"9810_CR52","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/humu.23406","volume":"39","author":"TR Rebbeck","year":"2018","unstructured":"Rebbeck, T. R. et al. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Hum. Mutat. 39(5), 593\u2013620 (2018).","journal-title":"Hum. Mutat."},{"issue":"3","key":"9810_CR53","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12032-018-1085-8","volume":"35","author":"A Shailani","year":"2018","unstructured":"Shailani, A. et al. A comprehensive analysis of BRCA2 gene: Focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors. Med. Oncol. 35(3), 18 (2018).","journal-title":"Med. Oncol."},{"issue":"1","key":"9810_CR54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ajhg.2012.05.021","volume":"91","author":"JJ Johnston","year":"2012","unstructured":"Johnston, J. J. et al. Secondary variants in individuals undergoing exome sequencing: Screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am. J. Human Genet. 91(1), 97\u2013108 (2012).","journal-title":"Am. J. Human Genet."},{"issue":"1","key":"9810_CR55","doi-asserted-by":"publisher","first-page":"e201204005","DOI":"10.5936\/csbj.201204005","volume":"1","author":"SL Clark","year":"2012","unstructured":"Clark, S. L. et al. Structure-function of the tumor suppressor BRCA1. Comput. Struct. Biotechnol. J. 1(1), e201204005 (2012).","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"10","key":"9810_CR56","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/cells13100824","volume":"13","author":"H Elshwekh","year":"2024","unstructured":"Elshwekh, H. et al. Assessing the impact of novel BRCA1 exon 11 variants on pre-mRNA splicing. Cells 13(10), 824 (2024).","journal-title":"Cells"},{"issue":"13","key":"9810_CR57","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.3390\/cancers13133171","volume":"13","author":"SM Caputo","year":"2021","unstructured":"Caputo, S. M. et al. 5\u2032 region large genomic rearrangements in the BRCA1 Gene in French families: Identification of a Tandem triplication and nine distinct deletions with five recurrent breakpoints. Cancers 13(13), 3171 (2021).","journal-title":"Cancers"},{"issue":"6","key":"9810_CR58","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jmoldx.2017.07.003","volume":"19","author":"AY Schmidt","year":"2017","unstructured":"Schmidt, A. Y. et al. Next-generation sequencing-based detection of germline copy number variations in BRCA1\/BRCA2: Validation of a one-step diagnostic workflow. J. Mol. Diagn. 19(6), 809\u2013816 (2017).","journal-title":"J. Mol. Diagn."},{"key":"9810_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07250-0","volume":"20","author":"FZ El Ansari","year":"2020","unstructured":"El Ansari, F. Z. et al. Screening of BRCA1\/2 genes mutations and copy number variations in patients with high risk for hereditary breast and ovarian cancer syndrome (HBOC). BMC Cancer 20, 1\u201311 (2020).","journal-title":"BMC Cancer"},{"issue":"3","key":"9810_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/ph17030333","volume":"17","author":"T Ismail","year":"2024","unstructured":"Ismail, T. et al. BRCA1 and its vulnerable C-terminal BRCT domain: Structure, function, genetic mutations and links to Diagnosis and treatment of breast and ovarian cancer. Pharmaceuticals 17(3), 333 (2024).","journal-title":"Pharmaceuticals"},{"issue":"6","key":"9810_CR61","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank, T. S. et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: Analysis of 10,000 individuals. J. Clin. Oncol. 20(6), 1480\u20131490 (2002).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"9810_CR62","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/gim.2017.96","volume":"20","author":"JL Caswell-Jin","year":"2018","unstructured":"Caswell-Jin, J. L. et al. Racial ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet. Med. 20(2), 234\u2013239 (2018).","journal-title":"Genet. Med."},{"issue":"5","key":"9810_CR63","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1634\/theoncologist.2012-0452","volume":"18","author":"NM Lindor","year":"2013","unstructured":"Lindor, N. M. et al. BRCA1\/2 sequence variants of uncertain significance: A primer for providers to assist in discussions and in medical management. Oncologist 18(5), 518\u2013524 (2013).","journal-title":"Oncologist"},{"key":"9810_CR64","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s10689-017-9985-x","volume":"16","author":"X Gabald\u00f3 Barrios","year":"2017","unstructured":"Gabald\u00f3 Barrios, X. et al. Molecular characterization and clinical interpretation of BRCA1\/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: Clinical\u2013pathological features in BRCA carriers and non-carriers. Fam. Cancer 16, 477\u2013489 (2017).","journal-title":"Fam. Cancer"},{"issue":"3","key":"9810_CR65","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1002\/cam4.5091","volume":"12","author":"LP Rweyemamu","year":"2023","unstructured":"Rweyemamu, L. P. et al. Breast cancer in East Africa: Prevalence and spectrum of germline SNV\/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania. Cancer Med. 12(3), 3395\u20133409 (2023).","journal-title":"Cancer Med."},{"issue":"4","key":"9810_CR66","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.esmoop.2021.100235","volume":"6","author":"M Bono","year":"2021","unstructured":"Bono, M. et al. Impact of deleterious variants in other genes beyond BRCA1\/2 detected in breast\/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: Looking over the hedge. ESMO Open 6(4), 100235 (2021).","journal-title":"ESMO Open"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09810-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09810-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:38:57Z","timestamp":1757263137000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09810-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9810"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09810-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Cairo university National cancer institute IRB approval number: 2301\u2013305-051.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"26067"}}